Ashok M Amin

6881407, Apr 19, 2005

Aug 10, 2001

09/925970

Ashok Amin - Union NJ, US
Steven Abramson - Rye NY, US

A61K039/395

4241331, 4241411, 4241431

Hepatitis can be treated by administering to a patient in need thereof an effective amount of a compound that neutralizes the effects of secreted TNFalpha. Two types of these compounds are extracellular ligand binding proteins of the human p75 TNF receptor, such as etanercept (Enbrel), and humanized monoclonal antibodies that neutralize the activity of TNFalpha, such as inflixamab (Remicade).

20030202977, Oct 30, 2003

Jun 16, 2003

10/461423

Ashok Amin - Union NJ, US
Steven Abramson - Rye NY, US

New York University - New York NY

A61K039/395

424/146100, 424/144100

Agents with integrin-afffecting activity, including antibodies and molecules having the antigen-binding portion of such antibodies, are used to regulate inflammatory mediators, including TL-1, IL-6, IL-8, nitric oxide, PGEand MMPs.

59197757, Jul 6, 1999

Apr 16, 1998

9/061286

Ashok R. Amin - Union NJ
Steven B. Abramson - Rye NY
Lorne M. Golub - Smithtown NY
Nungavaram S. Ramamurthy - Smithtown NY
Thomas F. McNamara - Port Jefferson NY
Robert A. Greenwald - Melville NY
Howard Trachtman - New Rochelle NY

The Research Foundation of The State University of New York - Stony Brook NY
Hospital For Joint Diseases - New York NY

A61K 3165

514152

The invention is a method of inhibiting the production of nitric oxide (NO) in an in vivo, in vitro, or ex vivo biological system. The method employs a tetracycline compound to inhibit the production of NO and/or to inhibit the expression or activity of an inducible isoform of nitric oxide synthase (iNOS). Preferably, the tetracycline compound has inhibitory activity for metalloproteinases. Also it is preferred that the tetracycline compound is provided to the biological system in an amount which has little or no antibacterial activity in the system. Accordingly, preferred tetracycline compounds are tetracycline compounds which have be modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by NO production mediated by iNOS, including, for example, inflammatory conditions.

57598363, Jun 2, 1998

Mar 27, 1995

8/410739

Ashok R. Amin - Union NJ
Steven B. Abramson - Rye NY

Hospital For Joint Diseases - New York NY

C12N 902
C12N 999

435189

An novel isoform of inducible nitric oxide synthase (OA-NOS) has been identified in osteoarthritis-affected articular cartilage. Some properties, including molecular weight, are similar to the constitutive isoform of neuronal nitric oxide synthase (ncnos) while other properties share similarity with the previously identified inducible nitric oxide (iNOS). Acetylating agents, such as aspirin and N-acetylimidazole act on both iNOS and OA-NOS by inhibiting their catalytic activities. A method is provided to screen for acetylating agents that inhibit OA-NOS, and the selective inhibition of OA-NOS by inhibitory agents is determined by comparison to a panel of different isoforms of nitric oxide synthase.

57893950, Aug 4, 1998

Aug 30, 1996

8/697815

Ashok R. Amin - Union NJ
Steven B. Abramson - Rye NY
Lorne M. Golub - Smithtown NY
Nungavaram S. Ramamurthy - Smithtown NY
Thomas F. McNamara - Port Jefferson NY
Robert A. Greenwald - Melville NY
Howard Trachtman - New Rochelle NY

The Research Foundation of State University of New York - Albany NY
Hospital for Joint Diseases - New York NY

A61K 3165
C12N 999
C12N 904
C12N 906

514152

A method is disclosed for inhibiting endogenous production of nitric oxide (NO) in an in vivo, in vitro, or ex vivo mammalian system. The method employs a tetracycline compound to inhibit production of NO and/or to inhibit the expression or activity of an inducible isoform of nitric oxide synthase (iNOS). Preferably, the tetracycline compound has inhibitory activity for metalloproteinases. Also it is preferred that the tetracycline compound is provided to the mammalian system in an amount which has little or no antibacterial activity in the system. Accordingly, preferred tetracycline compounds are tetracycline compounds which have be modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by NO production mediated by iNOS, including, for example, inflammatory conditions.

63199106, Nov 20, 2001

Dec 17, 1998

9/213149

Ashok Amin - Union NJ
Steven Abramson - Rye NY
Inoravadan V. Patel - Hillsborough NJ

Hospital for Joint Diseases - New York NY

A61K 3165

514152

Chemically modified tetracyclines are a new class of non-steroidal anti-inflammatory drugs which inhibit cyclooxygenase-2 and tumor necrosis factor alpha. These chemically modified tetracyclines are used in a method for inhibiting COX-2, which in turn inhibits PGE. sub. 2, and/or inhibiting TNF. alpha. They are also used in a method for treating a disease or disorder associated with elevated activities of COX-2 (i. e. , increased production of PGE. sub. 2) and/or TNF. alpha.